Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP To Finalize Medicare Rx Model Formulary In 2004; VA System As Guide?

Executive Summary

The Veterans Affairs medication classification system is likely to serve as a starting point for the U.S. Pharmacopeia's development of a model formulary for the Medicare prescription drug benefit
Advertisement

Related Content

Pharmacologic Class In Label Should Be Set By Formulary, Not Industry – ASHP
Pharmacologic Class In Label Should Be Set By Formulary, Not Industry – ASHP
USP Medicare Formulary Design Committee To Host Public Meeting Aug. 27
USP Medicare Formulary Design Committee To Host Public Meeting Aug. 27
Medicare Rx Formulary Will Have More Than VA’s 30 Classes
“Lifestyle” Drug Coverage Will Be Federal Policy Issue Under Medicare Rx
Pfizer Weighs In On E-Prescribing: Pricing Granularity Critical
Medicare Part D Regs Coming Soon; CMS Plans To Finalize Regions In 2004
Medicare Formularies Will Have Two Drugs Per Class; CMS To Track Atypicals
Medicare Formularies Will Have Two Drugs Per Class; CMS To Track Atypicals
Advertisement
UsernamePublicRestriction

Register

PS043996

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel